Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
2. Ft-2102
1. 1887014-12-1
2. Ft-2102
3. Olutasidenib [usan]
4. Olutasidenib (ft-2102)
5. 0t4imt8s5z
6. 5-[[(1s)-1-(6-chloro-2-oxo-1h-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile
7. (s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
8. Ft2102
9. 2-pyridinecarbonitrile, 5-(((1s)-1-(6-chloro-1,2-dihydro-2-oxo-3-quinolinyl)ethyl)amino)-1,6-dihydro-1-methyl-6-oxo-
10. 5-(((1s)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
11. 5-{[(1s)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino}-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
12. 5-[[(1s)-1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino]-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
13. Olutasidenib [inn]
14. Unii-0t4imt8s5z
15. Olutasidenib [who-dd]
16. Chembl4297610
17. Schembl17603134
18. Gtpl10319
19. Amy16919
20. Ex-a4523
21. Bdbm50506474
22. Example 26 [us9834539b2]
23. Nsc818621
24. S8949
25. Ft-2102ft-2102
26. Nsc-818621
27. Ac-36556
28. Hy-114226
29. Cs-0080183
30. D87221
31. 5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
32. Pwv
| Molecular Weight | 354.8 g/mol |
|---|---|
| Molecular Formula | C18H15ClN4O2 |
| XLogP3 | 2.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 3 |
| Exact Mass | 354.0883534 g/mol |
| Monoisotopic Mass | 354.0883534 g/mol |
| Topological Polar Surface Area | 85.2 Ų |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 745 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
About the Company : Sichuan Taienkang Pharmaceutical Co., Ltd., established in 2020, is a subsidiary of Guangdong Taienkang Pharmaceutical Co., Ltd. The company specializes in the R&D, production, and...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Details:
Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Lead Product(s): Olutasidenib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Rigel Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 19, 2025

Lead Product(s) : Olutasidenib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Details : Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2025

Details:
Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): Olutasidenib,Cladribine,Cytarabine,Venetoclax,Gilteritinib Fumarate,Ruxolitinib Phosphate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Rigel Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 24, 2025

Lead Product(s) : Olutasidenib,Cladribine,Cytarabine,Venetoclax,Gilteritinib Fumarate,Ruxolitinib Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Olutasidenib + Co-targeted Therapy Safety In R/R IDH1-mutated Myeloid Malignancies
Details : Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Lead Product(s): Olutasidenib,Venetoclax,Azacitidine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Justin Watts
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 20, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Olutasidenib,Venetoclax,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Justin Watts
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 20, 2025

Details:
Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myelomonocytic, Chronic.
Lead Product(s): Olutasidenib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Rigel Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2024

Lead Product(s) : Olutasidenib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myelomonocytic, Chronic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Decitabine and venetoclax in combination with Rezlidhia (olutasidenib) in patients with mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML).
Lead Product(s): Olutasidenib,Decitabine,Venetoclax
Therapeutic Area: Oncology Brand Name: Rezlidhia
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Olutasidenib,Decitabine,Venetoclax
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Rigel Enrolls First Patient in Phase 1b/2 Trial of REZLIDHIA® for mIDH1 AML
Details : Decitabine and venetoclax in combination with Rezlidhia (olutasidenib) in patients with mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML).
Product Name : Rezlidhia
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 05, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The agreement aims to develop and commercialize Rezlidhia (olutasidenib) in all current and potential indications in Japan, the Republic of Korea and Taiwan.
Lead Product(s): Olutasidenib,Inapplicable
Therapeutic Area: Oncology Brand Name: Rezlidhia
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Kissei Pharmaceutical
Deal Size: $162.5 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement September 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Olutasidenib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Kissei Pharmaceutical
Deal Size : $162.5 million
Deal Type : Licensing Agreement
Rigel Expands REZLIDHIA® Partnership with Kissei for Japan, Korea, Taiwan
Details : The agreement aims to develop and commercialize Rezlidhia (olutasidenib) in all current and potential indications in Japan, the Republic of Korea and Taiwan.
Product Name : Rezlidhia
Product Type : Miscellaneous
Upfront Cash : $10.0 million
September 03, 2024

Details:
Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myelodysplastic Syndromes.
Lead Product(s): Olutasidenib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Rigel Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2024

Lead Product(s) : Olutasidenib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myelodysplastic Syndromes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 22, 2024

Details:
Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.
Lead Product(s): Olutasidenib,Venetoclax,Decitabine,Cedazuridine
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Rigel Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2024

Lead Product(s) : Olutasidenib,Venetoclax,Decitabine,Cedazuridine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Rigel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The collaboration aims to conduct a Phase 2 clinical trial to evaluate Rezlidhia (olutasidenib) in combination with temozolomide for treating high-grade glioma harboring an IDH1 mutation.
Lead Product(s): Olutasidenib,Temozolomide
Therapeutic Area: Oncology Brand Name: Rezlidhia
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: CONNECT
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Olutasidenib,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : CONNECT
Deal Size : $3.0 million
Deal Type : Collaboration
Rigel Collaborates with CONNECT for Olutasidenib Phase 2 Trial in Glioma
Details : The collaboration aims to conduct a Phase 2 clinical trial to evaluate Rezlidhia (olutasidenib) in combination with temozolomide for treating high-grade glioma harboring an IDH1 mutation.
Product Name : Rezlidhia
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 04, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioma.
Lead Product(s): Olutasidenib,Temozolomide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Nationwide Children’s Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 08, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Olutasidenib,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Nationwide Children’s Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Olutasidenib and Temozolomide in HGG
Details : Olutasidenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 08, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
82
PharmaCompass offers a list of Olutasidenib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Olutasidenib manufacturer or Olutasidenib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Olutasidenib manufacturer or Olutasidenib supplier.
PharmaCompass also assists you with knowing the Olutasidenib API Price utilized in the formulation of products. Olutasidenib API Price is not always fixed or binding as the Olutasidenib Price is obtained through a variety of data sources. The Olutasidenib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Olutasidenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Olutasidenib, including repackagers and relabelers. The FDA regulates Olutasidenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Olutasidenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Olutasidenib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Olutasidenib supplier is an individual or a company that provides Olutasidenib active pharmaceutical ingredient (API) or Olutasidenib finished formulations upon request. The Olutasidenib suppliers may include Olutasidenib API manufacturers, exporters, distributors and traders.
click here to find a list of Olutasidenib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Olutasidenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Olutasidenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Olutasidenib GMP manufacturer or Olutasidenib GMP API supplier for your needs.
A Olutasidenib CoA (Certificate of Analysis) is a formal document that attests to Olutasidenib's compliance with Olutasidenib specifications and serves as a tool for batch-level quality control.
Olutasidenib CoA mostly includes findings from lab analyses of a specific batch. For each Olutasidenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Olutasidenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Olutasidenib EP), Olutasidenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Olutasidenib USP).